Among recipients of subcutaneous implantable cardioverter defibrillators, the omission of defibrillation testing (DT) was not associated with significant differences in mortality, or in the rates of ...
Medtronic (NYSE: MDT) today announced new data supporting its Aurora and OmniaSecure defibrillation technology offerings.
SAN DIEGO, CA—Use of a subcutaneous implantable cardioverter-defibrillator (S-ICD) appears to have some advantages over transvenous devices for patients with an ICD indication but no need for pacing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback